ClinicalTrials.gg
RecruitingNCT07550673Updated Apr 24, 2026

Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis(UPRISE)

A Phase 4 interventional study of upadacitinib and Infliximab in Acute Severe Ulcerative Colitis, sponsored by Xijing Hospital of Digestive Diseases. Recruiting at 4 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Xijing Hospital of Digestive Diseases · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
226
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing upadacitinib in Colitis, Ulcerative — 8 open to participants now, 10 under way, 3 of them phase 3. upadacitinib · Colitis, Ulcerative.

Planned enrollment
6th of 12
226 · median 180
Started
2026
with 4 others
Phase 4
6 of 12
6 open now
Registered
11th of 12
by date
Lead sponsor
1 of 12
Xijing Hospital of Digestive Diseases

Among the 12 studies testing upadacitinib in Colitis, Ulcerative, this one is the 6th largest by planned enrollment, is one of 5 that started in 2026, is one of 6 in phase 4, and was the 11th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

8 of the 12 studies testing upadacitinib in Colitis, Ulcerative are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About upadacitinib

upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing upadacitinib in Colitis, Ulcerative, or all of them as a file.
02

Study summary

This clinical trial aims to evaluate the comparative efficacy and safety of upadacitinib versus infliximab as second-line treatments for acute severe ulcerative colitis, addressing the following key questions: (1) Can upadacitinib as a second-line therapy effectively induce remission in acute severe ulcerative colitis with efficacy non-inferior to infliximab? (2) What adverse reactions may occur with upadacitinib in the treatment of acute severe ulcerative colitis? Researchers will also compare the efficacy of upadacitinib with that of corticosteroids to assess its therapeutic effect. Participants will be assigned to either the upadacitinib group (receiving upadacitinib extended-release tablets 45 mg once daily for 8 weeks, followed by 30 mg once daily) or the infliximab group (receiving an initial dose of 5 mg/kg, with additional doses at week 2, week 6, and every 8 weeks thereafter at the same dose). The treatment duration is 3 months, with outpatient visits for examinations and tests every two weeks. Patients will record their bowel movements and symptoms such as abdominal pain, and undergo colonoscopy, ultrasound examinations, and blood tests at specified time points.

03

Conditions studied

  • Acute Severe Ulcerative Colitis

Browse trials for

Keywords

  • Acute severe ulcerative colitis
  • Upadacitinib
  • second-line treatments
  • infliximab
  • Randomized Controlled Trial
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with ASUC
  • Aged 18 years or older.
  • No gender restriction.

Exclusion criteria

Exclusion Criteria:

  • Presence of , allergy, or intolerance to upadacitinib or infliximab.
  • Patients requiring immediate colectomy; diagnosis of Crohn's disease; confirmed intestinal infection; hemodynamic instability; cytomegalovirus infection; current .
  • Presence of severe underlying systemic diseases involving the heart, lungs, liver, kidneys, hematologic system, or other organ systems.
  • Pregnant or breastfeeding women.
  • Unwilling to participate in the clinical study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
226 participants (estimated)

Study arms

  • Experimental
    Upadacitinib group

    Upadacitinib extended-release tablets 45 mg once daily for 8 weeks, then adjusted to 30 mg once daily.

    Drug: upadacitinib

  • Active comparator
    Infliximab group

    receiving an initial dose of 5 mg/kg, with additional doses at week 2, week 6, and every 8 weeks thereafter at the same dose

    Drug: Infliximab

Interventions

  • receiving upadacitinib extended-release tablets 45 mg once daily for 8 weeks, followed by 30 mg once daily

  • receiving an initial dose of 5 mg/kg, with additional doses at week 2, week 6, and every 8 weeks thereafter at the same dose

06

What researchers measure

Primary outcomes

  1. Clinical response by day 7

    clinical response by day 7 (defined as a reduction in Lichtiger score to \<10 points with a decrease of ≥3 points from baseline improvement in rectal bleeding, and decreased stool frequency to ≤4 per day).

    Time frame: The primary outcome was assessed by the investigator between days 3 and 7, with patients recorded as clinical responders if they had the primary outcome on any day in this assessment window.

Secondary outcomes

  1. clinical response by day 14

    Defined as mayo score decrease of ≥30% and ≥3 points from baseline, accompanied by a decrease in the rectal bleeding subscore of ≥1 point or an absolute rectal bleeding subscore of 0 or 1.

    Time frame: day 14

  2. clinical remission by day 28, day 42, and day 90

    Total Mayo score ≤2 points and no individual subscore \>1 point.

    Time frame: day 28, day 42, and day 90

  3. Endoscopic response by day 90

    A decrease in MES score of ≥1 point, or a decrease of ≥50% from baseline.

    Time frame: day 90

  4. Endoscopic remission by day 90

    MES score ≤1

    Time frame: day 90

  5. Endoscopic+clinical response

    Partial Mayo score ≤1 and MES ≤1

    Time frame: day 90

  6. Clinical +FcP remission

    Partial Mayo score ≤1 and FcP≤250mg/kg

    Time frame: day 90

  7. Clinical +CRP remission

    Partial Mayo score ≤1 and CRP≤5mg/L

    Time frame: day 90

  8. Histologic remission

    typically defined as the absence of signs of neutrophilic infiltration. The specific criterion is a score below 2B.0, i.e., no increased neutrophils in the lamina propria.

    Time frame: day 90

  9. Histologic improvement

    when assessing treatment efficacy, a score ≤ 3.1 (intraepithelial neutrophilic infiltration involving \< 50% of crypts) is used as the threshold for histologic improvement.

    Time frame: day 90

  10. Adverse Reactions

    Adverse Reactions

    Time frame: day 90

  11. IBD questionnaire scores

    IBDQ and fatigue questionnaire scores,The total score ranges from 32 to 224 points. The closer the score is to 224, the less the patient is troubled by the disease and the higher their quality of life.

    Time frame: day 0 and day 90

  12. PROMIS-Fatigue SF-7a

    Patient-Reported Outcome Measurement Information System Fatigue Short Form 7a.The total score ranges from 7 to 35 points. The higher the score, the more severe the fatigue caused by the disease, and timely attention to the patient's condition is needed.

    Time frame: day 0 and day 90

07

Study locations

4 of 4 sites recruiting
08

References and documents

Publications

  • Honap S, St-Pierre J, Colwill M, Patel K, Le Berre C, Caron B, Nogami A, Kobayashi T, Altwegg R, Laharie D, Hebuterne X, Nachury M, Roblin X, Uzzan M, Kotze PG, Lukas M, Vieujean S, D'Amico F, Albshesh A, Guillo L, Fumery M, Nancey S, Ye BD, Bergemalm D, Halfvarson J, Buisson A, Karmiris K, Rubin DT, Vicaut E, Peyrin-Biroulet L; ATTRACT Study Group. Comparative Effectiveness of Tofacitinib vs Upadacitinib for the Treatment of Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2026 Mar;24(3):784-793. doi: 10.1016/j.cgh.2025.07.025. Epub 2025 Jul 26. PubMed 40721074 ↗
  • Choy MC, Li Wai Suen CFD, Con D, Boyd K, Pena R, Burrell K, Rosella O, Proud D, Brouwer R, Gorelik A, Liew D, Connell WR, Wright EK, Taylor KM, Pudipeddi A, Sawers M, Christensen B, Ng W, Begun J, Radford-Smith G, Garg M, Martin N, van Langenberg DR, Ding NS, Beswick L, Leong RW, Sparrow MP, De Cruz P. Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol. 2024 Nov;9(11):981-996. doi: 10.1016/S2468-1253(24)00200-0. Epub 2024 Sep 2. PubMed 39236736 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2028, 23 months after the start.

Of 48 non-industry phase 4 interventional studies under Colitis, Ulcerative, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 66. This study's planned 23 months is below that.

Counting every sponsor, half of 63 studies reached it within 43 months; a quarter within 25 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2026
First posted
Apr 24, 2026
StartActual
Apr 20, 2026
Primary completionEst.
Apr 1, 2028
CompletionEst.
Nov 1, 2028
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07550673
Lead sponsor
Xijing Hospital of Digestive Diseases
Responsible party
Yongquan Shi (Professor, Xijing Hospital of Digestive Diseases) — Principal investigator
First posted
Apr 24, 2026
Start date
Apr 20, 2026
Primary completion
Apr 1, 2028 (estimated)
Completion
Nov 1, 2028 (estimated)
Last update
Apr 24, 2026

Study contacts

Yongquan Shi, Ph.D
Contact
shiyquan@fmmu.edu.cn
86-029-84771535

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion